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Abstract
Background: Pancreatic islet encapsulation is one way to address the disadvantages of islet transplantation. Not
only does encapsulation involve bidirectional diffusion of nutrients, oxygen, and glucose, but also it protects the
graft from the recipient’s immune reaction. The high mobility group box 1 (HMGB1), one of higher expression
proteins in islet, can be secreted from transplanted islets and induce the inflammation. Therefore, the regulation of
HMGB1-mediated inflammation is very important for successful islet transplantation. In this study, we used the
HMGB1 A box, an antagonist of HMGB1 receptor in the immune cells, in the encapsulation of isolated islets as a
new strategy.
Result: For co-encapsulation of HMGB1 A box protein with islets, we evaluated the distribution of alginate bead
diameter. The average diameter of empty alginate bead was similar to that of alginate bead with islets. When
different concentrations of HMGB1 A box protein was co-encapsulated with islets, it did not affect the viability and
insulin secretion function of the islets. When the alginate beads with islets plus HMGB1 A box protein were
cultured with macrophage, the amount of TNF-α secreted from the macrophages was significantly attenuated
when compared to cultivation of unencapsulated islets or encapsulated islets. When the alginate beads with islets
plus HMGB1 A box protein were intraperitoneally xenotransplanted into the diabetic mice, the survival rate of the
islets was strongly improved with 2-fold.
Conclusion: Collectively, these results suggested that the encapsulation of HMGB1 A box protein might offer a
protective effect in islet transplantation.
Keywords: Alginate bead, Encapsulation, High mobility group box 1 (HMGB1), HMGB1 A box, Pancreatic islet
transplantation
Background
Type 1 Diabetes Mellitus (T1DM) is chronic disease that
results from the autoreactive T lymphocyte-mediated de-
struction of beta cells in the pancreatic islets of Langerhans
[1]. This autoimmune cell destruction against islets leads to
a deficiency of insulin hormone in the body. To cure
T1DM, insulin protein can be administered via injection or
insulin pump, which are not an ultimate strategy due to
their limited action. Alternatively, pancreatic islet trans-
plantation has been recognized as a promising treatment
approach for T1DM because transplanted islets can
dynamically and directly control the blood glucose levels of
diabetic patients [2]. However, it also has limitations, such
as immune rejection reactions leading to its failure [1, 3]. In
clinic, therefore, administration of various kinds of im-
munosuppressive medications has been used to prevent
islet graft rejection; however, these medications can cause
several adverse effects such as hypertension and renal fail-
ure in the patients during long-term administration [4, 5].
There have been many prior attempts to overcome the
disadvantages islet transplantation, including especially
pancreatic islet encapsulation with alginate hydrogel.
This islet encapsulation remedy may remove the need
for immunosuppressive drugs because the alginate bead
could inhibit the recognition of host’s immune cells
through ‘immune-isolation’, thereby reducing the inflam-
mation [6, 7]. Also, alginate bead can allow the bidirec-
tional diffusion of nutrients, oxygen, and glucose to the
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islets [8]. However, the encapsulated islets are under the
condition of hypoxia at the center of a large bead [9–11].
The reason is the diffusion distance of oxygen and nu-
trients into the large-sized alginate bead (diameter:
500 ~ 1,000 μm). The islet cells is under the hypoxia-
induced cell death, thereby releasing intracellular mole-
cules [11, 12]. One of the releasing intracellular molecules
is high-mobility group box 1 (HMGB1) protein. It is
known that this HMGB1 is a non-histone protein involved
in the regulation of transcription [13]. It has three do-
mains, called the A box, B box, and C terminus tail. The
HMGB1 A box has an anti-inflammatory activity, whereas
HMGB1 B box has an inflammatory activity [14, 15]. Like
a cytokine, it can be released from activated immune cells
including macrophages, monocytes and dendritic cells,
which can eventually mediate infection, injury and inflam-
mation [13]. Interestingly, it was reported that pancreatic
islets expressed predominantly the HMGB1 protein [16].
Therefore, if islets were encapsulated in the alginate bead,
they could highly release the HMGB1 protein during
hypoxia-induced cell death. Recently, several literature
suggested that the release of HMGB1 was strongly corre-
lated to early loss in islet transplantation [16–18]. Based
on these finding, it has been required to develop a strategy
for inhibition of the HMGB1 activity.
To this end, here we introduced co-encapsulation of
islets with HMGB1 A box fragment. We assumed that the
HMGB1 A box fragment could inhibit HMGB1-mediated
inflammation via competitive inhibition on the Toll-like
receptors (TLRs) and the receptor for advanced glycation
end products (RAGE) onto the immune cells (Scheme 1).
Here we tested whether co-encapsulation of HMGB1 A
box could inhibit the inflammation by using in vitro culti-
vation with macrophage and in vivo transplantation in
diabetic animal model.
Methods
Islet isolation and culture
Seven-week old outbred Sprague–Dawley (SD) male rats
and inbred BALB/c male mice were purchased from the
Nara-Bio Company (Seoul, Republic of Korea). The ani-
mals were raised in ventilated cages under specific
pathogen-free conditions at our institution. All animal
procedures were approved by Hanyang University through
the Institutional Animal (IACUC/ HY-IACUC-13–030A).
The islets of Langerhans were isolated from the outbred
SD rats using collagenase P (1 mg/mL; Roche, Basel,
Switzerland). Collagenase P was injected into the pancreas
through a bile duct. The pancreas organ was then
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Scheme 1 The pancreatic islet and HMGB1 A box protein were co-encapsulated in the alginate bead. The encapsulated HMGB1 A box protein
may protect islets from HMGB1-mediated inflammation via competitive inhibition against TLR and/or RAGE on immune cells. By this action, this
co-encapsulation of HMGB1 A box protein could reduce early graft loss in islet transplantation
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separation and purification stages, the islets were washed
with Medium-199 (Sigma, St. Louis, MO, USA). Finally,
the isolated islets were cultured in RPMI-1640 (Invitrogen,
Carlsbad, CA, USA) containing 10 % fetal bovine serum
(FBS; Sigma) and 1 % penicillin-streptomycin solution
(Gibco, Carlsbad, CA, USA) for 2 days.
Preparation of HMGB1 A box protein
A bacterial host strain of E. coli BL21(λDE3) was used to
express the vector of rHMGB1A-His6. The pET21a-
rHMGB1A-His6 was cultured overnight in 2 ml LB
medium supplemented with 50 μg/ml ampicillin in a
shaking incubator at 37 °C. Bacteria were then transferred
to the LB medium and cultured in the same conditions.
The expression of rHMGB1A-His6 was induced using
isopropyl-β-D-thiogalactopyranoside (IPTG, Sigma) for
6 h in culture at 25 °C. The bacteria were collected and
suspended in 50 mM of NaH2PO4 (pH 8.0) containing
300 mM NaCl, 10 mM imidazole and 1 mM phenyl-
methylsulfonylfluoride (PMSF). The lysates were elicited
using centrifugation at 10,000 × g for 30 min at 4 °C. To
purify the rHMGB1A-His6 fusion protein in the lysates,
nickel-chelate affinity chromatography (Probond resin, Invi-
trogen) was used. Unbound proteins were passed through
the equilibration buffer, and the bound rHMGB1A-His6
peptides were eluted using a step-gradient of imidazole.
The eluted fractions were assayed using the BCA assay kit
(Pierce, Rockford, IL, USA). The fraction of purified protein
was pooled, dialyzed with phosphate buffered saline (PBS)
and stored at −80 °C until use.
Generation of alginate bead
Encapsulator Biotech (EncapBioSystems Inc., Greifensee,
Switzerland) was used to prepare alginate beads. Briefly,
0.15 g of alginic acid (Sigma) was dissolved in 10 ml of dis-
tilled water. The 1.5 % alginate solution was injected 10 ml
syringe and then installed Encapsulator biotech. The
Alginate-based bead generator conditions included a fre-
quency of 1700 Hz, electrode 1100 V, stirrer 5 rpm, pump
33.8 ml/min and nozzle diameter of 300 μm. Calcium
chloride solution (3 %) was also used for gelation of alginate
beads. The alginate beads were 3-times washed with Dulbe-
co’s modified eagle’s medium (DMEM; GenDEPOT, Barker,
TX, USA). The size distribution of alginate bead was
calculated to evaluate the effect of islets and HMGB1 A
box protein to the formation of alginate bead.
Toxicity of HMGB1 A box to isolated islets
Before encapsulation, pancreatic islets were directly ex-
posed to each concentration (0, 2.5, 5, and 10 μM) of
HMGB1 A box protein and cultured at 37 °C for 1 or
4 days. After the incubation period, the viability of the
islets was measured using a CCK-8 assay kit (Dojindo
Laboratories, Tokyo, Japan). On the other hand, islets
were encapsulated with HMGB1 A box protein-
containing alginate beads using the Encapsulator, and
were cultured in DMEM medium for 1 or 4 days. The
viability of the encapsulated islet was measured with
the CCK-8 assay.
Glucose responsiveness of islet encapsulated with HMGB1
A box protein
The glucose-stimulated insulin secretion (GSIS) assay
was performed to evaluate the function of islets. The en-
capsulated islet was incubated in Krebs Ringer buffered
HEPES (pH 7.4) with 0.1 % (w/v) bovine serum albumin
containing 2.8 mM low glucose at 37 °C for 1 h. After
this pre-incubation, the encapsulated islets were incu-
bated at 37 °C for 2 h in 2.8 mM and 20.2 mM high
glucose solution, subsequently. The amount of insulin
protein secreted by the islets in the low- and high-
glucose solution was measured using a rat Insulin
enzyme-linked immunosorbent assay kit (ELISA; Alpco
Diagnostics, NH, USA). Finally, the measured insulin
content was divided by the DNA content measured by
a DNA Assay kit (Invitrogen) for the compensation of
size variation of islets.
Co-culture of activated macrophages with islet-containing
alginate bead
The alginate beads with islets and HMGB1 A box pro-
tein were cultured with Raw 264.7 macrophage cells in
order to assess the anti-inflammatory effect of HMGB1
A box protein. To activate the Raw 264.7 cells, they
were treated with 500 ng/ml HMGB1 protein for
3 days. After activation, islet-containing alginate beads
were co-cultured for three days. To evaluate the effect
of HMGB1 A box protein, the amount of TNF-α re-
leased from the activated macrophage was measured
by using ELISA (KOMA, Seoul, Republic of Korea).
Xenotransplantation of alginate bead with islets and
HMGB1 A box protein
To evaluate whether the HMGB1 A box protein could
regulate the inflammation in vivo, the alginate beads
with islets and HMGB1 A box protein were xenotrans-
planted into the peritoneum of streptozotocin-induced
diabetic BALB/c mice (1000 islets/mice). After xeno-
transplantation, the blood glucose levels of the recipients
were daily measured.
Statistical analysis
All values are represented as means ± S.E.M (Standard
error of the mean). The error bars represent the S.E.M.
Comparisons were performed with ANOVA one-way tests
(sigma Plot, Systat Software, Inc., San Jose, CA, USA).
P-values < 0.05 were considered statistically significant.
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Results and discussion
Characterization of alginate bead
After generation of alginate beads, we confirmed the
morphology and size of the alginate bead with islets. The
empty alginate beads and islet-containing alginate beads
were uniform in circular shape (Fig. 1a). The average size
of the empty alginate beads and islet-containing alginate
beads was about 500 μm and 600 μm, respectively. 4.6 ×
10 [4] beads per 1 ml of alginate solution were generated.
The size range of the empty beads was between 300 μm
and 1000 μm. The polydistribution index (PDI) of the
alginate-based bead was ± 1.07, indicating that the beads
were relatively uniform (Fig. 1b). On the other hand, in
the case of islet-containing alginate solution, 4.4 × 10 [4]
beads per 1 ml of alginate solution were generated. These
ranged between 300 μm and 1200 μm in size. The islet-
containing alginate beads were also uniform with a PDI
of ±1.08. Therefore, based on the findings, the condition
of alginate beads using Encapsulator Biotech instrument
was acceptable for islet encapsulation.
Toxicity evaluation of HMGB1 A box to isolated islets
To evaluate whether HMGB1 A box protein was toxic
to islets, the viability of islets was measured during culti-
vation with different concentration of HMGB1 A box
protein for 4 days (Fig. 2a). After 1-day incubation with
2.5, 5, and 10 μM of HMGB1 A box protein, the viability
of islets was 83.3 ± 3.4, 86.6 ± 7.6, and 104.3 ± 6.9 %, re-
spectively. After 4-day incubation, the viability of islets
was 82.3 ± 13.3, 89.5 ± 5.9, and 84.9 ± 8.0 %, respectively.
There were no statistical differences in viability between
the groups. Moreover, the morphologies of islets treated
with HMGB1 A box protein were not significantly differ-
ent from that of untreated control islets (0 μM) after
four days (Fig. 2b). From these results, we concluded that
HMGB1 A box protein did not affect islet viability. The
reason was that HMGB1 A box protein The HMGB1 A
box concentration in alginate co-encapsulation with
pancreatic islets was optimized at 10 μM.
Next, we carried out the islet encapsulation with algin-
ate hydrogel to evaluate the viability of encapsulated is-
lets in the presence of HMGB1 A box protein (Fig. 2c).
The viability of the encapsulated islets without or with
the HMGB1 A box protein after one day was 85.3 ± 0.7
and 83.8 ± 1.2 %, respectively. After 4 days, their viability
without or with the HMGB1 A box was 80.4 ± 2.2 and
81.5 ± 5.5 %, respectively. There were no significant dif-
ferences between the groups. Therefore, we found that
HMGB1 A box protein did not affect the viability of is-
lets in the alginate bead. However, the viability of both
groups was slightly reduced when compared with unen-
capsulated control islets. The large bead size affects islet
cell viability because it is more difficult for nutrients and
oxygen to diffuse across a larger bead than it is for them
to diffuse across a smaller bead. Therefore, larger beads
are more likely to induce hypoxia than are smaller ones.
Glucose responsiveness of islet encapsulated with HMGB1
A box protein
It is very important to evaluate the functionality of islets
in the alginate bead. Here, we carried out glucose-
stimulated insulin secretion (GSIS) using low and high
concentration of glucose solution (Fig. 3a). In the case
unencapsulated control islets at low (2.8 mM) and high
(20.2 mM) glucose concentrations, the secreted insulin
content was 0.058 ± 0.002 and 0.182 ± 0.003 ng/ng DNA,
respectively. With regard to the encapsulated islets,
0.058 ± 0.001 and 0.156 ± 0.001 ng/ng DNA of insulin
were secreted at low and high glucose, respectively. In
the encapsulated islet with HMGB1 A box protein,
0.065 ± 0.003 and 0.151 ± 0.006 ng/ng DNA of insulin
were secreted at low and high glucose, respectively.
There were no statistically significant differences between
the groups. The stimulation index (SI value; SI = insulin
Fig. 1 Characterization of alginate hydrogel bead. a Morphology of the alginate bead (upper panel) and the alginate bead with the pancreatic
islet (under panel). Scale bar = 500 μm. b Size distribution of the alginate bead and alginate bead with pancreatic islets
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Fig. 3 Glucose responsiveness of islets after co-encapsulation with HMGB1 A box protein. a Glucose-stimulated insulin secretion (GSIS) assay of
the unencapsulated islet, encapsulated islet alone, and encapsulated islet with HMGB1 A box protein according to low glucose (2.8 mM, black bar) and
high glucose (20.2 mM, white bar) treatment for 2 h, sequentially. b Stimulation index (SI) values of the unencapsulated islet, encapsulated islet alone,
and encapsulated islet with HMGB1 A box protein. Data were expressed as means ± SEM (n = 5). N.S = no significant
Fig. 2 Cytotoxicity of HMGB1 A box protein to islets. a Effect of the HMGB1 A box (0, 2.5, 5, and 10 μM) on pancreatic islet viability for 4 days
treatment. The black dot indicates the HMGB1 A box treated islet viability at day 1, and the white dot at day 4. b Morphology images of islets
treated with HMGB1 A box protein for 4 days. c Viability of islets after co-encapsulation with HMGB1 A box protein. The black bar indicates the
islet viability at day 1 and the white bar at day 4
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content of each groups in 20.2 mM glucose solution/insu-
lin content of each groups in 2.8 mM glucose solution)
was 3.1 ± 0.1 in the unencapsulated islet, 2.7 ± 1.1 in the
encapsulated islet, and 2.3 ± 0.2 in the encapsulated islet
with the HMGB1 A box protein (P > 0.05) (Fig. 3b). In
general, the SI value > 2 demonstrate that islet has good
responsiveness according to different concentration of
glucose. Therefore, we concluded that the functionality of
the pancreatic islets in alginate bead was normally main-
tained even though their SI values were no significantly
less than that of unencapsulated control islets.
Co-culture of activated macrophages with islet-containing
alginate bead
Early after pancreatic islet transplantation, the activation
of immune cells such as macrophages plays a crucial
role in islet graft damage [16]. We tested the effect of
the HMGB1 A box protein for protection of islets
against macrophages (Fig. 4). Macrophage raw 264.7
cells were activated by treatment of HMGB1 protein
(500 ng/ml) before co-culture with alginate beads. With-
out co-culture of alginate beads, the activated macrophages
secreted 3.0 ± 0.1 ng/ml of TNF-α. During co-culture with
unencapsulated islets, the highest TNF-α secretion
level (7.5 ± 0.3 ng/ml) was significantly detected. In the
case of co-culture with the encapsulated islets, the se-
creted amount of TNF-α was no significantly reduced
(6.3 ± 0.5 ng/ml). For co-culture with the encapsulated
islets with HMGB1 A box protein, the secretion of
TNF-α cytokine was dramatically reduced (3.8 ±
0.3 ng/ml) (P < 0.001). The inhibition of the HMGB1-
activated macrophage indicated that HMGB1 A box
protein could be act as a competitive inhibitor against
TLR and/or RAGE on macrophage. To do that, the
HMGB1 A box protein could be released from the algin-
ate bead external milieu. Therefore, the co-encapsulation
of HMGB1 A box protein could be used to protect islets
from the inflammation in vivo.
Xenotransplantation of alginate bead with islets and
HMGB1 A box protein
To evaluate whether the alginate bead with islets and
HMGB1 A box protein was protected in vivo, the algin-
ate beads were xenotransplanted into the peritoneal cav-
ity of diabetic mice (Fig. 5). All diabetic mice reached
normal blood glucose levels (<200 mg/dL) within three
days of xenotransplantation. However, this effect was not
sustained in the encapsulated islet group (3 day survival).
In contrast, in the encapsulated islets with HMGB1 A box
protein, the mice maintained normal blood glucose levels
for longer than did those without the HMGB1 A box pro-
tein (5 day survival). This effect may be secondary to lon-
ger graft survival in the HMGB1 A box protein compared
to that in the encapsulated islets alone. However, the effect
of HMGB1 A box protein was not dramatically stronger.
The reason was that xenotransplantation had generally
powerful immune reaction. So, the encapsulated islet (with
and without the HMGB1 A box protein) had a weak effect
in xenotransplantation models. Therefore, further studies
are needed to clarify the in vivo effect of encapsulated islets
with the HMGB1 A box protein in allotransplantation
model.
Fig. 4 Secreted amount of TNF-α of activated macrophage during
co-culture of alginate bead with islets and HMGB1 A box protein.
HMGB1-activated macrophage Raw 264.7 cells were co-cultured with
unencapsulated islets, encapsulated islets, and encapsulated islets
with HMGB1 A box protein. Data were represented as means ± SEM
(n = 5). *P < 0.001
Fig. 5 Non-fasting blood glucose levels of diabetic mice after
xenotransplantation of alginate bead with rat islets and HMGB1 A
box protein. Encapsulated SD-rat islets with and without HMGB1 A
box protein were xenotransplanted into peritoneal cavity of diabetic
BALB/c mice. Black line represented transplantation of the encapsulated
islet alone, and red line represented the encapsulated islet with HMGB1
A box protein
Jo et al. Biomaterials Research  (2015) 19:21 Page 6 of 7
Conclusion
Islet encapsulation is one potential solution to the limi-
tations of islet transplantation. However, encapsulation
can induce the secretion of HMGB1 protein during the
hypoxia-induced cell death. However, the encapsulated
islet with the HMGB1 A box protein attenuated HMGB1-
mediated inflammation in vitro and in vivo. However, we
expected that HMGB1 A box protein might be effective in
allotransplantation models.
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